Clinical trial
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
NCT03371108
Study timeline
Study start (actual)2017-10-31Date precision: day
Registry last updated2022-04-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Diabetes Mellitus, Type 2unresolved
Interventions
Gan & Lee Insulin Glargine InjectionBIOLOGICAL
Lantus®BIOLOGICAL
Sponsors & collaborators
Gan and Lee Pharmaceuticals, USAlead sponsor
Mapped research locations
MiamiFlorida, United States4AustinTexas, United States3ChicagoIllinois, United States2BirminghamAlabama, United States2ColumbusOhio, United States2ChattanoogaTennessee, United States2San AntonioTexas, United States1PhoenixArizona, United States1Salt Lake CityUtah, United States1Las VegasNevada, United States1SacramentoCalifornia, United States1LouisvilleKentucky, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03371108 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.